Clinical Tailoring of Baricitinib 2 mg in Atopic Dermatitis: Baseline Body Surface Area and Rapid Onset of Action Identifies Response at Week 16

INTRODUCTION: Baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, is indicated in the European Union and Japan for treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. In the ongoing, placebo-controlled, phase 3 trial BREEZE-AD5, once-daily o...

Descripción completa

Detalles Bibliográficos
Autores principales: Silverberg, Jonathan I., Boguniewicz, Mark, Waibel, Jill, Weisman, Jamie, Strowd, Lindsay, Sun, Luna, Ding, Yuxin, Feely, Meghan, Nunes, Fabio P., Simpson, Eric L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776967/
https://www.ncbi.nlm.nih.gov/pubmed/34846636
http://dx.doi.org/10.1007/s13555-021-00640-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776967/
https://www.ncbi.nlm.nih.gov/pubmed/34846636
http://dx.doi.org/10.1007/s13555-021-00640-7

Ejemplares similares